Tdap Booster Vaccine Receives Expanded FDA Indication
FDA granted Sanofi Pasteur’s Adacel Tdap absorbed vaccine expanded indication to include repeat vaccinations for tetanus, diphtheria and pertussis.
Common Misconceptions Are the Cause for Almost Half of U.S. Adults Skipping the Flu Shot
A new survey shows more than 40 percent of Americans haven’t been vaccinated against the flu and aren’t planning to be due to misconceptions.
Severe Flu Increases Risks for Pregnant Women and Their Babies
A new study shows pregnant women hospitalized in the ICU with flu are four times more likely to deliver prematurely and four-and-a-half times more likely to have a baby of low birth weight.
$293 Million Awarded by HHS to Expand Primary Healthcare Workforce
The U.S. Department of Health and Human Services’ (HHS) Health Resources and Services Administration (HRSA) has awarded $293 million in awards to primary healthcare clinicians and students through the National Health Service Corps (NHSC) and Nurse Corps programs.
CMS’s New Oncology Care Model Aims to Provide Better Care for Chemotherapy Patients
CMS has developed the Oncology Care Model (OCM) to provide higher quality and more highly coordinated oncology care at the same or lower cost to Medicare.
CMS to Strengthen and Enhance Oversight and Transparency of Medicare Accrediting Organizations
CMS takes steps to enhance and strengthen its oversight and quality transparency of accrediting organizations.
New Hemophilia A Treatment Approved by FDA
The U.S. Food and Drug Administration (FDA) has approved Bayer’s Jivi (BAY94-9027) as a preventive treatment for bleeding in hemophilia A.
Cervical Cancer Vaccines Safe and Effective in Girls and Women
A study that examined data from more than 73,000 girls and women shows vaccines designed to prevent infection with human papillomavirus (HPV) are effective in protecting against precancerous cervical lesions in women, particularly in those vaccinated between age 15 and 26 years.
Single-Dose Flu Drug Given Priority Review by FDA
Genentech’s baloxavir marboxil, an experimental, single-dose flu drug, has been given priority review by the U.S. Food and Drug Administration (FDA).
Neonatal Fc Receptor Antagonist Efgartigimod Sustainably Reduces Circulating IgG Level in Humans
Investigators from the Belgian biotechnology company argenx and U.S. collaborators conducted a PhaseI clinical study to assess a novel modified antibody Fc fragment (efgartigimod) that reduces the circulating IgG level by blocking neonatal Fc receptor-mediated IgG recycling.